Skip to search boxSkip to navigationSkip to main content

A dynamic model for assessing universal Hepatitis A vaccination in Canada

  • C. T. Bauch(corresponding author)
    ,
  • ,
  • B. Z. Pham
    ,
  • M. Krahn
    ,
  • V. Gilca
    ,
  • B. Duval
*Corresponding author for this work
  • University of Guelph
    ,
  • GlaxoSmithKline
    ,
  • University of Toronto
    ,
  • Université Laval
Scholary Output:
Contribution to journal
Article
Peer-review

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Vaccination against Hepatitis A virus (HAV) in Canada is currently targeted toward high-risk groups. However, universal vaccination has been adopted in several other countries with a similar disease burden. Here we develop an age-structured compartmental model of HAV transmission and vaccination in Canada to assess potential universal vaccination strategies. The model predicts that universal vaccination at age 1 (respectively 4, 9, 15), with phasing out of targeted vaccination, would reduce reported incidence by 60% (respectively 52, 36, 31%) and mortality attributable to HAV by 56% (respectively 45, 26, 25%), relative to continued targeted vaccination, over 80 years.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 1719-1726 (8 pages)

Journal (Volume, Issue Number)

Vaccine (Volume 25, Issue 10)

Publication milestones

  • Published - 02/26/2007

Publication status

Published - 02/26/2007

ISSN

0264-410X

Publication IDs

  • Scopus: 33846691934
  • PubMed: 17229493

Publication metrics

Metrics

SciVal
citations
21
Fractional count
1
Fractional count
0.13
Fractional count
7
Fractional count
0.88
Fractional count
1
Fractional count
1
Scopus
citations
SciVal
FWCI
1.23
SciVal
Author count
8
SciVal
Paper percentile
74

PlumX, opens in new tab

Captures
31
Citation count
27

Funding Details

This work was supported by a Canadian Institutes of Health Research Industry-Partnered Grant in conjunction with GlaxoSmithKline.
FundersFunding numbers
GSK
-
CIHR
-